Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?

Key Points

• Strategic deal with Regeneron: Telix announced a collaboration to develop next‑generation radiopharmaceuticals with potential value up to $2.1bn, and several analysts have reiterated/raised buy ratings and price targets that imply substantial upside (consensus PT ~ $21).
• Shares volatile and trading lower: The stock gapped down at the open (prior close $11.24 to $10.75), last around $10.99 and down roughly 3.7% on elevated volume, showing market uncertainty despite the headline deal.
• Fundamental risks remain: Telix missed the latest quarter (EPS -$0.01 vs $0.05 est.; revenue $206.7M vs $421.5M est.) and carries meaningful leverage (debt/equity ~1.08), which could cap upside if development or commercial milestones slip.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) shares gapped down before the market opened on Tuesday . The stock had previously closed at $11.24, but opened at $10.75. Telix Pharmaceuticals shares last traded at $10.9860, with a volume of 135,170 shares trading hands.

Key Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Strategic collaboration with Regeneron to jointly develop and commercialize next‑generation radiopharmaceutical therapies — the deal was reported with up to $2.1bn in potential value, signaling large commercial and milestone upside if programs progress. Telix and Regeneron Announce Strategic Radiopharma Collaboration
• Positive Sentiment: Analyst support increased: Wedbush reaffirmed an “outperform” rating with a $22 PT and HC Wainwright reaffirmed a “buy” with a $20 PT — both imply substantial upside from current levels and likely boosted investor demand. Analyst Coverage (Benzinga)
• Neutral Sentiment: Widespread media coverage (MSN, Yahoo, other outlets) is amplifying the headline and driving trading volume and volatility as investors parse deal terms and program scope. Regeneron, Telix strike radiopharmaceutical cancer deal worth up to $2.1bn
• Negative Sentiment: Fundamental headwinds remain: Telix missed EPS and revenue expectations in its last reported quarter (EPS -$0.01 vs. $0.05 est.; revenue $206.7M vs. $421.5M est.), and the company carries leverage (debt/equity ~1.08). Those factors increase execution risk and could cap upside if development or commercial milestones slip. Telix Pharmaceuticals (TLX) Market Data and Earnings

Wall Street Analyst Weigh In

Several equities analysts have recently commented on TLX shares. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Monday. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research report on Monday, January 19th. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. Citigroup boosted their price target on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a "buy" rating in a research report on Tuesday, February 24th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $21.13.

Telix Pharmaceuticals Trading Down 3.7%

The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The stock's 50-day simple moving average is $7.98 and its two-hundred day simple moving average is $8.71.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) last posted its quarterly earnings data on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.06). The business had revenue of $206.72 million for the quarter, compared to analyst estimates of $421.50 million. As a group, analysts anticipate that Telix Pharmaceuticals Limited will post 0.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Rhumbline Advisers increased its position in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock valued at $25,000 after acquiring an additional 1,392 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Telix Pharmaceuticals in the fourth quarter worth about $89,000. IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals in the second quarter worth about $213,000. OLD Mission Capital LLC bought a new position in shares of Telix Pharmaceuticals in the fourth quarter worth about $111,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Telix Pharmaceuticals in the third quarter worth about $243,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.